Table 6.
Nrf2-related therapeutic effects of curcumin in cardio/pulmonary disorders (I.P.: intraperitoneal).
| Type of Disease | Animals | Dose Range | Cell Line | Dose Range | Targets and Other Pathways |
Function | Ref. |
|---|---|---|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF) | - | - | LMSCs | 2.5–20 µM | HO-1, Bcl-2, Bax, Caspase-3, AKT |
CUR via the AKT/Nrf2/HO-1 axis could protect murine LMSCs from H2O2. | [50] |
| High Altitude Pulmonary Edema (HAPE) |
Male SD rat | 50 mg/kg, orally, 1 h before exposure | A549 | 10 μM | HIF1-α, HO-1, VEGF, GST |
CUR via upregulating Nrf2 and HIF1-α could play a role as a potential strategy for the prevention of HAPE. | [51] |
| Asthma | Female specific pathogen-free (SPF) BALB/c mice | 200 mg/kg, I.P.,1 h prior to OVA | RAW264.7 | 5–50 μM | HO-1, NF-κB, TNF-α, IL-1β, IL-6 |
CUR via activating the Nrf2/HO-1 axis could ameliorate airway inflammation in asthma. | [52] |
| Chronic Heart Failure (HF) | Male C57BL/6 mice | 50 mg/kg, daily, supplied with osmotic minipumps, for 8 weeks | - | - | HO-1, SOD2, myogenin, MyoD, MURF1, Atrogen-1, |
CUR via upregulating the Nrf2 could ameliorate exercise intolerance in HF mice. | [53] |